Afya Limited

Afya Limited (AFYA) Stock Analysis

$14.530

+0.010 (+0.07%)At close

Loading chart…
High
14.670
Open
14.520
VWAP
14.54
Volume
194.16K
Mkt Cap
1.53B
Low
14.420
Amount
2.82M
EV/EBITDA, TTM
2.02

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.

AI analysis of Afya Limited (AFYA)

Buy

Afya Ltd is a good buy right now due to its strong financial performance, reflected in a gross margin of 61.59% and a forward P/E ratio of 7.86. The recent revenue growth of 7% year-over-year and the significant analyst upgrades provide a solid foundation for potential price appreciation. However, the risk is highlighted by the insider selling activity, which has increased by 1215.03% over the last month, indicating potential concerns among insiders.

Valuation Metrics

The current forward P/E ratio for Afya Limited (AFYA) is 7.86, compared to its 5-year average forward P/E of 10.93.

Forward P/E

Undervalued
5Y Average P/E
10.93
Current P/E
7.86
Overvalued
13.61
Undervalued
8.25

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
6.34
Current EV/EBITDA
2.02
Overvalued
8.56
Undervalued
4.13

Forward P/S

Strongly Undervalued
5Y Average P/S
2.08
Current P/S
0.30
Overvalued
2.95
Undervalued
1.20

Alphio AI Price Scenarios for AFYA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AFYA

$28.55

Scenario price

B

Base

Base · 50%AFYA

$24.23

Scenario price

B

Bear

Bear · 25%AFYA

$20.66

Scenario price

Whales holding AFYA

S

SoftBank Group Corp.

+ HoldingAFYA

-15.12%

3M Return

Events Timeline

2026-08-24 (ET)

10:00:00

Afya and Yduqs Discuss Potential Business Combination

2025-11-12 (ET)

18:14:48

Afya announces Q3 adjusted EBITDA of R$398.9M, a 14.6% increase year-over-year

2025-11-07 (ET)

08:54:49

Afya Reveals Expansion of Medical Seats at ITPAC Porto Nacional

News

AFYA FAQ — answered by Alphio AI

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform. It operates in the Academic & Educational Services sector.

Afya Ltd is a good buy right now due to its strong financial performance, reflected in a gross margin of 61.59% and a forward P/E ratio of 7.86. The recent revenue growth of 7% year-over-year and the significant analyst upgrades provide a solid foundation for potential price appreciation. However, the risk is highlighted by the insider selling activity, which has increased by 1215.03% over the last month, indicating potential concerns among insiders.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading